Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice

被引:0
作者
Kaur, Gurveer [1 ]
Nwabufo, Chukwunonso K. [1 ,2 ,3 ]
机构
[1] OneDrug Inc, Toronto, ON, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada
[3] Hosp Sick Children, Program Translat Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
adverse drug reactions; healthcare provider; implementation; patient; personalized medicine; pharmacogenetics; pharmacogenetic testing device; point-of-care; PHARMACISTS PERCEPTION; CONTEXT; EXPERIENCES; SUPPORT; POINT;
D O I
10.1097/FPC.0000000000000541
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
ObjectiveThis study aims to understand patient and healthcare provider perspectives on the integration and application of pharmacogenetics (PGx) testing in routine clinical practice.MethodsTwo anonymous online surveys were distributed globally for healthcare providers and patients respectively on the Qualtrics platform (version 3.24). The surveys were distributed through social platforms, email, and posters with QR codes from 27 October 2023 to 7 March 2024. The surveys evaluated participant familiarity with PGx, previous experience with PGx testing, perceived implementation challenges, and opinions on point-of-care (PoC) PGx testing devices.ResultsThis study collected 78 responses from healthcare providers and 98 responses from patients. The results revealed that 64% of healthcare providers had some level of familiarity with PGx, however, PGx testing in clinical practice was low. The primary challenges identified by healthcare providers included limited access to testing and lack of knowledge on PGx test interpretation. In contrast, 52% of patient respondents were aware of PGx testing, with a significant association between awareness and positive opinions toward PGx. Both healthcare providers and patients recognized the value of PoC PGx testing devices, with 98% of healthcare providers and 71% of patients believing PoC devices would improve the accessibility and implementation of PGx testing. Comparative analysis revealed a statistically significant difference in PGx awareness between healthcare providers and patients, with providers being more informed.ConclusionImproved PGx awareness, training, clinical guidelines, and PoC PGx testing devices may help promote the implementation of PGx-guided treatments in routine clinical practice.
引用
收藏
页码:236 / 245
页数:10
相关论文
共 50 条
  • [31] Pharmacogenetic approaches in the treatment of alcohol use disorders: Addressing clinical utility and implementation thresholds
    Hendershot C.S.
    Addiction Science & Clinical Practice, 9 (1)
  • [32] Retrospective pharmacogenetic analysis of a pediatric patient under anticoagulant treatment: Clinical case
    Cavieres, Mirta
    Suarez, Marcelo
    Veron, Gabriel
    Abel Quinones, Luis
    Miguel Varela, Nelson
    BIOMEDICA, 2021, 41 (03): : 403 - 408
  • [33] Oncology healthcare provider perspectives on caring for diverse patients fifteen years after Unequal Treatment
    Villalobos, Aubrey V. K.
    Phillips, Serena
    Zhang, Yuqing
    Crawbuck, Graham S. N.
    Pratt-Chapman, Mandi L.
    PATIENT EDUCATION AND COUNSELING, 2019, 102 (10) : 1859 - 1867
  • [34] Professionals' perspectives on existing practice and conditions for nurse-led gout care based on treatment recommendations: a qualitative study in primary healthcare
    Sedelius, Helene
    Tistad, Malin
    Bergsten, Ulrika
    Dehlin, Mats
    Iggman, David
    Wallin, Lars
    Svard, Anna
    BMC PRIMARY CARE, 2022, 23 (01):
  • [35] Patient and Provider Perspectives on HIV Stigma in Healthcare Settings in Underserved Areas of the US South: A Mixed Methods Study
    Crockett, Kaylee B.
    Turan, Bulent
    Whitfield, Samantha
    Kay, Emma Sophia
    Budhwani, Henna
    Fifolt, Matthew
    Hauenstein, Kris
    Ladner, Murray D.
    Sewell, Joshua
    Payne-Foster, Pamela
    Nyblade, Laura
    Batey, D. Scott
    Turan, Janet M.
    AIDS AND BEHAVIOR, 2022, 26 (SUPPL 1) : 112 - 124
  • [36] Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process
    Caudle, Kelly E.
    Klein, Teri E.
    Hoffman, James M.
    Mueller, Daniel J.
    Whirl-Carrillo, Michelle
    Gong, Li
    McDonagh, Ellen M.
    Sangkuhl, Katrin
    Thorn, Caroline F.
    Schwab, Matthias
    Agundez, Jose A. G.
    Freimuth, Robert R.
    Huser, Vojtech
    Lee, Ming Ta Michael
    Iwuchukwu, Otito F.
    Crews, Kristine R.
    Scott, Stuart A.
    Wadelius, Mia
    Swen, Jesse J.
    Tyndale, Rachel F.
    Stein, C. Michael
    Roden, Dan
    Relling, Mary V.
    Williams, Marc S.
    Johnson, Samuel G.
    CURRENT DRUG METABOLISM, 2014, 15 (02) : 209 - 217
  • [37] Implementation of a Patient-Provider Agreement to Improve Healthcare Delivery for Patients With Substance Use Disorder in the Inpatient Setting
    Wurcel, Alysse G.
    Yu, Sun
    Burke, Deirdre
    Lund, Amy
    Schelling, Kim
    Weingart, Saul N.
    Freund, Karen M.
    JOURNAL OF PATIENT SAFETY, 2021, 17 (08) : E1827 - E1832
  • [38] Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
    Stefan Russmann
    Ali Rahmany
    David Niedrig
    Karl-Dietrich Hatz
    Katja Ludin
    Andrea M. Burden
    Lars Englberger
    Roland Backhaus
    Andreas Serra
    Markus Béchir
    European Journal of Clinical Pharmacology, 2021, 77 : 709 - 716
  • [39] Incorporating patient perspectives in health technology assessments and clinical practice guidelines
    Hameen-Anttila, K.
    Komulainen, J.
    Enlund, H.
    Makela, M.
    Makinen, E.
    Rannanheimo, P.
    Sipila, R.
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2016, 12 (06) : 903 - 913
  • [40] Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
    Russmann, Stefan
    Rahmany, Ali
    Niedrig, David
    Hatz, Karl-Dietrich
    Ludin, Katja
    Burden, Andrea M.
    Englberger, Lars
    Backhaus, Roland
    Serra, Andreas
    Bechir, Markus
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (05) : 709 - 716